This on-demand webinar explores the development of oral solid dosage forms and the success factors required to achieve rapid prototype selection for clinical evaluation.
Webinar overview (40 minutes)
Dr Ian Lafferty delves into the formulation, analytical, and manufacturing strategies necessary for progressing from Phase I to Phase II clinical trials. Highlighting Upperton’s data-driven UpperSolve platform, the webinar outlines how minimal API input and early decision-making can streamline development, reduce timelines, and improve the likelihood of clinical and commercial success.
Key topics covered
Transition strategies from powder-in-bottle to tablets and capsules
Development timelines and practical considerations for Phase II readiness
Analytical method development and phase-appropriate validation
Stability study design and ICH-compliant testing requirements
Capsule vs. tablet selection and adaptable formulation approaches
Addressing bioavailability and manufacturability challenges
Special formulation needs for amorphous solid dispersions (ASDs)
Real-world case studies demonstrating successful Phase I–II transitions
Register for this on-demand webinar to gain insights into optimising oral dosage forms for clinical development and ensuring your formulation is ready for scale-up and regulatory success.
Speakers
Ian Lafferty
Chief Technical OFficer